ARCHIVES

Pharmaceutical Industry: IVAX Official Broder Objects To Orphan Drug Policies of FDA

This article is from The Cancer Letter archive.

Vol. 23 No. 18 | May 9, 1997

Download PDF Visit The Full Archive

Related Articles

Research Program For Biological Response Modifiers Outlined By DCT board Subcommittee

November 16, 1979

DCE director Adamson To Retire August 31

June 3, 1994

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

November 2, 2007

NCI Advisors Approve New $5 Million Program For Reagent Contracts.

July 10, 2009

Funding Opportunities: NCI Request for Applications

April 28, 2000

Institute Of Medicine: External Experts Should Vet Large Projects, Report Says.

June 20, 2003